GlaxoSmithKline (NYSE:GSK) was upgraded by equities research analysts at New Street Research from a “reduce” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, BenzingaRatingsTable reports.

Several other research analysts have also recently weighed in on the company. ValuEngine cut GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Jefferies Financial Group restated a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Societe Generale upgraded GlaxoSmithKline from a “sell” rating to a “buy” rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating in a research note on Friday, October 11th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $41.79.

NYSE:GSK traded down $0.39 during trading hours on Wednesday, reaching $41.88. 57,449 shares of the company traded hands, compared to its average volume of 2,261,648. The business’s 50-day moving average price is $41.75 and its two-hundred day moving average price is $40.78. The stock has a market capitalization of $105.63 billion, a P/E ratio of 13.25, a P/E/G ratio of 2.02 and a beta of 0.68. GlaxoSmithKline has a 1 year low of $36.41 and a 1 year high of $43.22. The company has a current ratio of 0.71, a quick ratio of 0.48 and a debt-to-equity ratio of 7.86.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $10.04 billion during the quarter, compared to analysts’ expectations of $9.55 billion. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. As a group, equities analysts anticipate that GlaxoSmithKline will post 2.96 EPS for the current year.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 177,777 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average price of $45.00 per share, for a total transaction of $7,999,965.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. SeaCrest Wealth Management LLC grew its holdings in shares of GlaxoSmithKline by 6.0% in the third quarter. SeaCrest Wealth Management LLC now owns 34,457 shares of the pharmaceutical company’s stock worth $1,471,000 after acquiring an additional 1,949 shares during the period. Ferguson Wellman Capital Management Inc. grew its holdings in shares of GlaxoSmithKline by 3.6% in the third quarter. Ferguson Wellman Capital Management Inc. now owns 125,124 shares of the pharmaceutical company’s stock worth $5,340,000 after acquiring an additional 4,320 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of GlaxoSmithKline in the third quarter worth $365,000. OmniStar Financial Group Inc. grew its holdings in shares of GlaxoSmithKline by 1.1% in the third quarter. OmniStar Financial Group Inc. now owns 30,569 shares of the pharmaceutical company’s stock worth $1,305,000 after acquiring an additional 321 shares during the period. Finally, KG&L Capital Management LLC grew its holdings in shares of GlaxoSmithKline by 24.2% in the third quarter. KG&L Capital Management LLC now owns 6,448 shares of the pharmaceutical company’s stock worth $275,000 after acquiring an additional 1,255 shares during the period. Hedge funds and other institutional investors own 11.13% of the company’s stock.

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Featured Article: What is a front-end load?

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.